Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1990 1
1992 1
1998 1
2000 2
2001 3
2002 2
2003 4
2004 3
2005 1
2006 5
2007 2
2008 1
2009 4
2010 11
2011 15
2012 15
2013 17
2014 8
2015 14
2016 13
2017 16
2018 23
2019 31
2020 28
2021 29
2022 38
2023 28
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

295 results

Results by year

Filters applied: . Clear all
Page 1
Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial.
Yuan L, Jia GD, Lv XF, Xie SY, Guo SS, Lin DF, Liu LT, Luo DH, Li YF, Deng SW, Guo L, Zeng MS, Cai XY, Liu SL, Sun XS, Li XY, Li SC, Chen QY, Tang LQ, Mai HQ. Yuan L, et al. Among authors: liu lt. Nat Commun. 2023 Aug 14;14(1):4893. doi: 10.1038/s41467-023-40402-x. Nat Commun. 2023. PMID: 37580352 Free PMC article. Clinical Trial.
Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial.
Liu LT, Liu H, Huang Y, Yang JH, Xie SY, Li YY, Guo SS, Qi B, Li XY, Chen DP, Jin F, Sun XS, Yang ZC, Liu SL, Luo DH, Li JB, Liu Q, Wang P, Guo L, Mo HY, Qiu F, Yang Q, Liang YJ, Jia GD, Wen DX, Yan JJ, Zhao C, Chen QY, Sun R, Tang LQ, Mai HQ. Liu LT, et al. Lancet Oncol. 2023 Jul;24(7):798-810. doi: 10.1016/S1470-2045(23)00232-2. Epub 2023 Jun 5. Lancet Oncol. 2023. PMID: 37290468 Clinical Trial.
Radiomic signatures reveal multiscale intratumor heterogeneity associated with tissue tolerance and survival in re-irradiated nasopharyngeal carcinoma: a multicenter study.
Liu T, Dong D, Zhao X, Ou XM, Yi JL, Guan J, Zhang Y, Xiao-Fei L, Xie CM, Luo DH, Sun R, Chen QY, Xing L, Guo SS, Liu LT, Lin DF, Chen YZ, Lin JY, Luo MJ, Yan WB, He ML, Mao MY, Zhu MY, Chen WH, Shen BW, Wang SQ, Li HL, Zhong LZ, Hu CS, Wu DH, Mai HQ, Tian J, Tang LQ. Liu T, et al. Among authors: liu lt. BMC Med. 2023 Nov 27;21(1):464. doi: 10.1186/s12916-023-03164-3. BMC Med. 2023. PMID: 38012705 Free PMC article.
Anti-pathogen stainless steel combating COVID-19.
Liu LT, Chin AWH, Yu P, Poon LLM, Huang MX. Liu LT, et al. Chem Eng J. 2022 Apr 1;433:133783. doi: 10.1016/j.cej.2021.133783. Epub 2021 Nov 25. Chem Eng J. 2022. PMID: 34853550 Free PMC article.
A phase II randomised controlled trial of adjuvant tumour-infiltrating lymphocytes for pretreatment Epstein-Barr virus DNA-selected high-risk nasopharyngeal carcinoma patients.
Liang YJ, Chen QY, Xu JX, Liu XF, Xia JC, Liu LT, Guo SS, Song B, Wang P, Li JB, Liu Q, Mo HY, Guo L, Sun R, Luo DH, He J, Liu YN, Nie CP, Tang LQ, Li J, Mai HQ. Liang YJ, et al. Among authors: liu lt. Eur J Cancer. 2023 Sep;191:112965. doi: 10.1016/j.ejca.2023.112965. Epub 2023 Jul 5. Eur J Cancer. 2023. PMID: 37540921 Clinical Trial.
Man With Progressive Exertional Dyspnea.
Liu LT, Fan SC, Yang CW, Hsu NC. Liu LT, et al. Ann Emerg Med. 2023 Feb;81(2):e19-e20. doi: 10.1016/j.annemergmed.2022.08.458. Ann Emerg Med. 2023. PMID: 36681433 No abstract available.
295 results